LabCorp's $85M Orchid Deal Depends On Divestment: FTC

Law360, New York (December 8, 2011, 5:04 PM EST) -- The Federal Trade Commission has asked Laboratory Corp. of America Holdings to divest a part of Orchid Cellmark Inc.’s paternity testing business in order to have its $85 million purchase of the rival DNA testing company approved, the agency said Thursday.

The FTC said it imposed the condition as part of a proposed agreement with the companies to resolve its complaint claiming that North Carolina-based LabCorp's April-announced acquisition of Orchid would have an anti-competitive effect on the paternity testing services market that government agencies rely on....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.